🇺🇸 FDA

Company profile · Sponsor

Vor

Vor Biopharma

VOR · NYSE biotech BOSTON, MA, USA
Pipeline
6
Drugs
0
Patents
8

Quick answer

Vor (VOR) is a biotech company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

Company facts

Ticker VOR
Exchange NYSE
Company type biotech
Headquarters BOSTON, MA, USA
SEC CIK 0001817229

Pipeline (6)

Search pipeline →

  1. Placebo contains excipients only and is visually indistinguishable from the Telitacicept, Telitacicept injection

    Vor

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  2. Telitacicept

    Vor

    Generalized Myasthenia Gravis

    phase 3 mab active

    1 trial

  3. Telitacicept

    Vor

    Primary Sjogren's Disease

    phase 3 mab active

    1 trial

  4. Telitacicept

    Vor

    Systemic Lupus Erythematosus

    phase 3 mab terminated

    2 trials

  5. VCAR33

    Vor

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

  6. VOR33

    Vor

    Leukemia, Myeloid, Acute

    phase 2 mab terminated

    1 trial

Patents (8)

Search patents →

  1. US 12403200

    Methods and compositions for treating autoimmune diseases

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12291576

    Anti-CD45 antibodies and conjugates thereof

    Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12251403

    Genetically engineered hematopoietic stem cells and uses thereof

    Expires Mon Mar 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12209135

    Anti-CD45 antibodies and conjugates thereof

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11975029

    Compositions and methods for inhibition of lineage specific proteins

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11903973

    Genetically engineered hematopoietic stem cells and uses thereof

    Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11571445

    Genetically engineered hematopoietic stem cells and uses thereof

    Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11559551

    Genetically engineered hematopoietic stem cells and uses thereof

    Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Vor?

Vor (VOR) is a biotech company. headquartered in BOSTON, MA, USA. listed on NYSE. NovaPharmaNews links 6 pipeline programs, 0 drugs, and 8 patents to this profile..

What pipeline programs does Vor sponsor?

We track 6 ClinicalTrials.gov-linked programs for Vor, including Placebo contains excipients only and is visually indistinguishable from the Telitacicept, Telitacicept injection and 5 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Vor company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.